
Press Release

Lund, March 14, 2014

Australia Patent Office Accepts Patent for RESP3000

Respiratorius announces that the Australian Patent Office issued a Notice of Acceptance for the patent application for RESP3000 series, designed for use in cardiovascular diagnostics with PET-camera. The priority date for the patent application is from December 2011, which means that the patent is in force until December 2031.

The substances in the RESP3000 series specifically binds to mitochondria, and since the heart muscle is rich in mitochondria allowing for high contrast and detailed PET images, which is also confirmed in the completed "proof of concept" study.

Markers to PET-cameras today attracts interest from a diagnostic perspective, since the images results in excellent resolution while the radiation dose can be kept low. This has contributed to a market in strong growth, with an estimated size of \$ 4 billion in 2018, and thereby a high level of activity in the industry.

"A patent approval in Australia complements previous approvals in the United States and Israel and provides additional commercial value to the project", says CEO Johan Drott in a statement.

This information is information which Respiratorius AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the above contact person's auspices, for publication on 14 March 2017

For further information, please contact:

Johan Drott
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com

Christer Fåhraeus
Ordf. Respiratorius AB
+46 705-60 90 00
christer.fahraeus@respiratorius.com

Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.